雙美 & Croma-Pharma (奧地利眼藥大廠) 合作玻尿酸

雙美：本公司102年3月22日董事會通過之重要議案 鉅亨網新聞中心2013-03-22 13:26:25 第二條第51款1.事實發生日:102/03/22 2.公司名稱:雙美生物科技股份有限公司（"雙"應為簡寫之"又又"，因系統會出現亂碼故以"雙"替代）3.與公司關係[請輸入本公司或子公司]:本公司4.相互持股比例:不適用5.發生緣由:本公司今日董事會通過之重要議案如下：(1)通過本公司與奧地利 Croma 藥廠簽訂「玻尿酸微整型針劑」代理合約案。(2)通過本公司一○一年度營業報告書、財務報表（含合併財務報表）及盈餘 分配表案。(3)通過修訂本公司章程提請股東會決議。(4)通過修訂「股東會議事規則」提請股東會決議。(5)通過修訂「董事及監察人選舉辦法」提請股東會決議。(6)通過本公司董事及監察人全面改選案提請股東會選舉。(7)通過解除本公司新任董事之競業禁止提請股東會決議。(8)通過召集一○二年股東常會案。(9)通過本公司一○二年股東常會受理持股1%以上股東提案之期間及地點。(10)通過本公司一○二年股東常會受理獨立董事候選人提名之期間及地點。(11)通過修訂內部控制制度、內部稽核實施細則及會計制度等管理辦法。(12)通過內部控制聲明書。(13)通過子公司－北京享贊國際貿易有限公司總經理派任案。6.因應措施:無。7.其他應敘明事項:無。

Croma-Pharma was founded in 1976 by Karin and Gerhard Prinz (both pharmacists).On June 15th 2007 Croma-Pharma became the new owner of the ophthalmic business field of Cornéal® Laboratoir, whereas Xcelens® was acquired in July 2007. Actually, CROMA is managed by Andreas Prinz (managing director of marketing and sales) and Martin Prinz (managing director of R&D and manufacturing). CROMA is operating in three business fields: orthopaedics, ophthalmology and dermatology (new segment). Moreover, caused by the recent acquisitions CROMA became a leading one-stop provider in cataract surgery and ranges among the top 5 companies of the European ophthalmic market. Thus, its business volume was doubled and CROMA has actually five subsidiaries in Germany, Poland, Spain, France and Romania. Additionally, CROMA is cooperating with numerous distributors worldwide. Nevertheless, the headquarters of CROMA will remain in Austria. The number of employees is 445 europeanwide. In 2008 we made a brand relaunch. Since second quarter 2008 the new CROMA logo replaces the former on. We also developed a new Corporate Identity and Corporate Design. This step was necessary due our two acquisitions.